What is KEYNOTE-189? Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses important points to note in NSCLC. In…
Browsing: Non-Small Cell Lung Cancer
Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer answers common questions on KEYNOTE-189. If the PD-L1 expression is less…
Shirish Gadgeel, MBBS of U-M Rogel Cancer Center @UMRogelCancer discusses an updated analysis on KEYNOTE-189: pembrolizumab or placebo plus pemetrexed…
JNJ-6372, a dual-targeting EGFR-MET bispecific antibody, is being investigated for adults with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion…
– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients…
– ALUNBRIG has Potential to Expand its Indication in ALK+ Metastatic Non-Small Cell Lung Cancer – – Prescription Drug User…
Thank you all for joining us for our live stream today! If you have questions please feel free to email…
Dr. Duma is an Assistant Professor and Thoracic Oncologist at @UWcarbone, University of Wisconsin Carbone Cancer Center, and Former Chief…
Rachel Brake @rachael_brake of Takeda discusses results from the phase 3 ALTA-1L trial and answers commonly asked questions regarding the…
ALUNBRIG Reduced the Risk of Disease Progression or Death by 76% in Patients whose Disease Had Spread to the Brain,…
Non-small-cell lung carcinoma (NSCLC) is an important area for the development and marketing of immuno-oncology (IO) drugs for most large…
Giorgio Scagliotti, MD @giorgioscaglio3 discusses the IASLC. _________ Read here:Â https://www.oncologytube.com/video/iaslc-open-comment-period-on-multidisciplinary-recommendations-for-pathologic-assessment-of-lung-cancer-resection-specimens-following-neoadjuvant-therapy-
Jianjun Zhang, MD of @MDAndersonNews discusses immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC. How will…
Jianjun Zhang, MD of @MDAndersonNews discusses immune and circulating tumor DNA profiling following radiation treatment for oligometastatic NSCLC.
The International Association for the Study of Lung Cancer today announces an open comment period for the “IASLC Multidisciplinary Recommendations…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________…
Suresh S. Ramalingam, MD @RamalingamMD of @WinshipAtEmory illustrates the next step in the phase III FLAURA trial in NSCLC. ________…
The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, according to preliminary results from a…
Ramaswamy Govindan, MD of Siteman Cancer Center explains the phase I KRAS inhibitor that is well tolerated by patients with…
Ramaswamy Govindan, MD of Siteman Cancer Center answers multiple questions regarding the phase I KRAS inhibitor well tolerated by patients…
A majority of patients with cancer don’t understand critical features of the genomic test results they receive when participating in…
Jonathan Goldman, MD of UCLA Health explains the full trial design of the CASPIAN trial. ______ In the Phase III…
Jonathan Goldman, MD of UCLA Health describes advances in SCLC. _______ In the Phase III CASPIAN trial IMFINZI at a…
Jonathan Goldman, MD of UCLA Health answers on the CASPIAN trial: is this practice changing? _______ In the Phase III…
For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
CancerGRACE is devoted to giving you the most up to date information about cancer and cancer treatment. In our ongoing…
CancerGRACE is devoted to giving you the most up to date information about cancer and cancer treatment. In our ongoing…
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Mohammed Jahanzeb, MD describes what he would like to see next in NSCLC research.
Mohammed Jahanzeb, MD explains the design of the study examining real-world treatment patterns and outcomes in U.S. ALK+ NSCLC patients…
Mohammed Jahanzeb, MD on how this data will affect clinicians today.
Mohammed Jahanzeb, MD answers questions asked by his colleagues.
Dr. Mohammed Jahanzeb, MD explains the health-related quality of life data from the ALTA-1L trial.
Dr. Mohammed Jahanzeb, MD provides Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs.…
Dr. Neal provides insight on the horizon for the upcoming year.
Dr. Neal explains the unmet needs for this patient population.
Dr. Neal provides the most commonly asked questions from colleagues and the recent findings in NSCLC.
Dr. Neal describes TAK-788’s safety profile and the side effects that come along with the drug’s use.
Dr. Neal provides details on TAK-788 Phase 1/2 study.
Dr. Neal explains what EGFR exon 20-mutant NSCLC is and how many patients have this particular mutation.
Drs. Jack West, Charu Aggarwal, and Benjamin Levy recently gathered to review top discussion points for Lung Cancer from ASCO…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…
Ravi Salgia, MD, Professor and Chair, Department of Medical Oncology and Therapeutics Research, Associate Director for Clinical Sciences, Arthur and…